Quick Links

 Cancer Immunotherapeutics Publications, 2006

2006, 2005, 2004, 2003, 2002

Cooper LJ, Ausubel L, Gutierrez M, Stephan S, Shakeley R, Olivares S, Serrano LM, Burton L, Jensen MC, Forman SJ, DiGiusto DL, DiGiusto DL. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma. Cytotherapy; 2006, 8(2): 105-117.

Han CH, Liu A, Schultheiss TE, Pezner RD, Chen YJ, Wong JY. Dosimetric comparisons of helical tomotherapy treatment plans and step-and-shoot intensity-modulated radiosurgery treatment plans in intracranl stereotactic radiosurgery. International Journal of Radiation Oncology Biology Physics; 2006, 65(2): 608-616.

Johnson LE, Frye TP, Arnot AR, Marquette C, Couture LA, Gendron FA, McNeel DG. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine; 2006, 24(3): 293-303.

Li CX, Kato M, Shiue L, Shively JE, Ares M, Lin RJ. Cell type and culture condition-dependent alternative splicing in human breast cancer cells revealed by splicing-sensitive microarrays. Cancer Research; 2006, 66(4): 1990-1999.

Li L, Yazaki PJ, Anderson AL, Crow D, Colcher D, Wu AM, Williams LE, Wong JY, Raubitschek A, Shively JE. Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody. Bioconjugate Chemistry; 2006, 17(1): 68-76.

Madsen MT, Anderson JA, Halama JR, Kleck J, Simpkin DJ, Votaw JR, Wendt RE, Williams LE, Yester MV. AAPM task group 108: PET and PET/CT shielding requirements. Medical Physics; 2006, 33(1): 4-15.

Serrano LM, Pfeiffer T, Olivares S, Numbenjapon T, Bennitt J, Kim D, Smith D, McNamara G, Al KZ, Rosenthal J, Forman SJ, Jensen MC, Cooper LJ. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posarcansplantation adoptive immunotherapy. Blood; 2006, 107(7): 2643-2652.

Wong JY, Liu A, Schultheiss T, Popplewell L, Stein A, Rosenthal J, Essensten M, Forman S, Somlo G. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: An alternative to standard total body irradiation. Biology of Blood and Marrow Transplantation; 2006, 12(3): 306-315.

Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA. A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies. Cancer Biother Radiopharm; 2006, 21(2): 88-100.

Chen C, Lee WH, Zhong L, Liu CP. Regulatory T cells can mediate their function through the stimulation of APCs to produce immunosuppressive nitric oxide. J Immunol; 2006, 176(6): 3449-60.

Yam P, Jensen M, Akkina R, Anderson J, Villacres MC, Wu J, Zaia JA, Yee JK. Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells. Mol Ther; 2006, 14(2): 236-44.

Miale TD, Wong JY, Ahmed I, Wagman LD. Multimodal management, including precisely targeted irradiation, in a severe refractory case of Evans syndrome. Pediatr Blood Cancer; 2006, 47(5 Suppl): 726-8.

Pigazzi A, Ellenhorn JD, Ballantyne GH, Paz IB. Robotic-assisted laparoscopic low anterior resection with total mesorectal excision for rectal cancer. Surg Endosc; 2006, 20(10): 1521-5.

Wong JY. Basic immunology of antibody targeted radiotherapy. Int J Radiat Oncol Biol Phys; 2006, 66(2 Suppl): S8-14.

Wong JY. Systemic targeted radionuclide therapy: potential new areas. Int J Radiat Oncol Biol Phys; 2006, 66(2 Suppl): S74-82.

Chen S, Masri S, Hong Y, Wang X, Phung S, Yuan Y, Wu X. New experimental models for aromatase inhibitor resistance. In Press. J. Steroid Biochem & Mol Biol; 2006.

Chen S, Masri S, Wang X, Phung S, Yuan Y, Wu X. What do we know about the mechanisms of aromatase inhibitor resistance?  In press. J. Steroid Biochem. & Mol. Biol; 2006.

Gu Z, Olafsen T, Sherman M, Leyton J, Witkosky M, Shively J, Raubitschek A, Morrison S, Wu A, Reiter R. Targeting, Imaging, and Therapy using a Humanized Anti-Prostate Stem Cell Antigen (PSCA) Antibody. In Press. Journal of Immunotherapy; 2006.

Hong Y, Yu B, Sherman M, Yuan Y, Zhou D, Chen S. Molecular basis for the aromatization reaction and irreversible inhibition of human aromatases by exemestance. In press. Mol. Endocrinol; 2006.

Wang X, Chen S. Aromatase destablizer: Novel action of exemestane, an FDA approved aromatase inhibitor. In press. Cancer Research; 2006.

Kaiser A, Schultheiss TE, Wong JY, Smith DD, Han C, Vora NL, Pezner RD, Chen YJ, Radany EH. Pitch, roll, and yaw variations in patient positioning. Int J Radiat Oncol Biol Phys; 2006, 66(3): 949-55.

Podnos YD, Tsai NC, Smith D, Ellenhorn JD. Factors affecting survival in patients with anal melanoma. Am Surg; 2006, 72(10): 917-20.

 Search

Go!
Advanced Search Options
News & Publications Search
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and urology by U.S.News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network®
(NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.